This is a repository copy of Novel function for the p38-MK2 signaling pathway in circulating CD1c1 (BDCA-11) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/115002/

Article:
Franks, Hester, Wang, Qunwei, Lax, Stephanie Joyce orcid.org/0000-0002-7000-9364 et al. (4 more authors) (2013) Novel function for the p38-MK2 signaling pathway in circulating CD1c1 (BDCA-11) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10. International Journal of Cancer. pp. 575-586. ISSN 1097-0215

https://doi.org/10.1002/ijc.28398

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10

Hester A. Franks¹, Qunwei Wang¹, Stephanie J. Lax¹, Mary K. Collins², David Escors³, Poulam M. Patel¹ and Andrew M. Jackson¹

¹Host: Tumour Interactions Group, Academic Unit of Clinical Oncology, University of Nottingham, United Kingdom
²MRC Centre for Medical Molecular Virology, University College London, United Kingdom
³Immunomodulation group, Navarabiomed-Fundacion Miguel Servet, National Health Service of Navarre, Pamplona, Navarra, Spain

There is growing interest in myeloid (my) dendritic cells (DC) as an alternative to monocyte-derived DC (moDC) for immunotherapy. However, in contrast to moDC, little is known regarding the effect of malignancy on the function, abundance or use of intracellular signaling pathways in myDC. Understanding the molecular detail of circulating myDC is therefore important for future use in advanced cancer. Advanced cancer patients had similar numbers of circulating myDC to cancer-free patients and healthy individuals, and secreted similar levels of IL-18, IL-6, IL-10, IL-12 and IL-23. However, myDC from some patients failed to secrete the Th1-cytokine IL-12. Surprisingly, inhibiting p38 (p38i) signaling (using BIRB0796 or SB203580) markedly increased IL-12 secretion by myDC. This is in complete contrast to what is established for moDC where inhibiting p38 ablates IL-12. Interestingly, this was specific to IL-12, since IL-10 was suppressed by p38i in both DC types. The opposing effect of p38i on IL-12 was evident at the transcriptional level and in both DC types was mediated through the p38-MK2 pathway but did not involve differential phosphorylation of the distal Rsk kinase. Importantly, where patient myDC did not secrete IL-12 (or after treatment with suppressive melanoma lysate), p38i restored IL-12 to normal levels. In contrast to p38, inhibiting the other MAPK pathways had similar consequences in both DC types. We show for the first time the differential use of a major intracellular signaling pathway by myDC. Importantly, there are sufficient circulating myDC in advanced cancer patients to consider development of adoptive immunotherapy.

Dendritic cells (DC) govern T-cell antigen-specificity, activation and polarization and their secretion of interleukin (IL)-12p70 (IL-12) induces Th1 and cytotoxic T cell (CTL) responses. Their role in anti-tumor immunity led to investigation of monocyte-derived DC (moDC) for immunotherapy. Circulating CD1c+ myeloid DC (myDC) are a physiological population of human DC which do not require in vitro generation and therefore have technical advantages over moDC. In addition, the potential immunotherapeutic benefits of myDC include more potent induction of T cell responses and more efficient chemotaxis toward T-cell chemokines. Whilst CD1c+ myDC share many general characteristics with moDC including cross-presentation, response to danger and priming T-cells, it has become increasingly clear that they do not function in exactly the same way and need to be studied in their own right. Key considerations yet to be addressed are whether there are sufficient myDC to use for immunotherapy in advanced cancer patients and whether they have normal function when isolated from the blood of cancer patients.

In order to design a clinically effective DC therapy, the ability to enhance Th1 polarization by increasing IL-12 secretion and suppress Treg induction via a reduction in IL-10 would be advantageous. We have studied other intracellular signaling pathways and demonstrated a novel role for the ATM DNA repair pathway in regulation of IL-23 and Th17 polarization in myDC and moDC. The MAPK pathways...
What’s new?
Dendritic cells (DCs) govern antigen specificity in T cells. DCs also secrete cytokines that regulate T-cell responses. This study explores the potential of circulating myeloid dendritic cells (myDC) for cancer immunotherapy. The authors examined intracellular signalling and cytokine secretion in myDCs, and found that when p38 MAPK is inhibited in these cells, IL-12p70 production is enhanced and IL-10 is suppressed. In contrast, monocyte-derived DCs (moDCs) require p38 MAPK for IL-12p70 production. These differences in intracellular signalling indicate that immunotherapy with myDCs may induce more potent anti-tumour immunity in combination with MAPK inhibitors.

Material and Methods
Reagents
Endotoxin-free reagents were used throughout. All media were based on RPMI 1640 with 1-glutamine (Sigma Gillingham, UK). DC medium contained vol/vol 10% fetal calf serum (FCS) and 1% sodium pyruvate (Sigma), T cell medium vol/vol 10% FCS, 1% 4-(2-hydroxyethyl)-1-piperazinethanesulfonic acid (HEPES), 1% sodium pyruvate, 1% nonessential amino acids and 20 μM 2-mercaptoethanol (Sigma) and MM418 medium 10% vol/vol FCS (PAA Yeovil, UK). Cytokines were recombinant human (rh) IL-4 (1,000 U/ml, Immunotools Friesoythe, Germany), rh granulocyte-macrophage colony stimulating factor (GM-CSF) (1,000 U/ml, Peprotech London, UK), rhIL-2 (50 U/ml) and rhIL-10 (Miltenyi Bergisch Gladbach, Germany). Ultrapure toll-like receptor (TLR) agonists were R848 (TLR7/8, 2.5 μg/ml, Invivogen San Diego, California) and Poly I:C (TLR3, 20 μg/ml, Sigma). T-cells were stimulated with mouse anti-human CD3 (OKT3, 1 μg/ml, produced in house) and CD28 (5 μg/ml, BD Pharmingen Oxford, UK). Mouse anti-human CD14 Phycoerythrin (PE) (Miltenyi Biotech), CD14 Fluorescein isothiocyanate, CD4 PE (both BD), CD45RA FITC (eBioscience Hatfield, UK) and CD45RO PE (Biolegend London, UK) were used with matched isotype controls. Small molecule inhibitors of MAPK (MAPKi) (UO126 and SB203580 and SP600125 Calbiochem Darmstadt, Germany) were used at 10 μM, BIRB0796 (Selleckchem Newmarket, UK) was used at 0.1–1.0 μM and MK2 inhibitor III (Calbiochem) at 1–3 μM.

Human participants
Heparinized blood was obtained from volunteers after written informed consent with ethical approval from Nottingham University Ethics Committee and Nottingham Research Ethics Committee 2. Melanoma and bowel cancer patients were recruited from Oncology Outpatient Clinics at Nottingham University Hospitals NHS Trust. Exclusion criteria were recent (<3 months) chemotherapy, any prior immunotherapy or anemia.

MyDC and moDC
Peripheral blood mononuclear cells (PBMC) were separated from heparinized blood by centrifugation over Histopaque 1077 (Sigma). MyDC were isolated using Miltenyi CD1c myDC kit as per manufacturer instructions. Briefly, B cells were depleted (anti-CD19 microbeads) before positive selection
of CD1c+ cells (routinely >95% pure by flow cytometry). MyDC were rested for 2 hr at 37°C before further treatment. CD1c− cells were incubated with anti-CD14 microbeads (Miltenyi), CD14+ monocytes (>95% pure) selected and resuspended at 0.5 × 10^6/ml in DC medium, IL-4 and GM-CSF. Half-volume medium/cytokines were added on day 3 and immature moDC harvested at day 5–6.

**In vitro stimulation**

Immature DC (10^5/well) were plated in DC medium with GM-CSF. GM-CSF was required for viability of myDC, and included with moDC for direct comparison. The presence of GM-CSF did not alter cytokine production by moDC, nor did it alter the effect of MAPKi on moDC (not shown). DC were treated with MM418 tumor-derived lysate (7.5 × 10^5 cells/ml) for 1 hr, MAPKi for 1 hr then poly I:C/R848 for 24 hr. To investigate the role of DC-derived IL-10 in regulation of IL-12, rhIL-10 was added (0.1–1.0 ng/ml) 4 hr after TLR stimulation (based on published data regarding time of DC secretion of IL-10). Supernatants were harvested and assayed by ELISA for IL-12p70 (BD biosciences), IL-23 (eBioscience), IL-1β, IL-10 (both R&D Abingdon, UK) and IL-6 (Immunotools).

**Preparation of tumor derived lysate**

MM418 cells were seeded into a 10-layer factory flask (Corning Costar Amsterdam, The Netherlands), harvested by trypsinization after 3 days, washed and resuspended at 1 × 10^7/ml in RPMI 1640. Lysate was prepared by five cycles of freeze-thaw as previously described. Mycoplasma testing was negative.

**Quantitative PCR**

MyDC and moDC were plated in DC medium containing GM-CSF. GM-CSF was required for viability of myDC, and included with moDC for direct comparison. The presence of GM-CSF did not alter cytokine production by moDC, nor did it alter the effect of MAPKi in moDC (not shown). DC were treated with MM418 tumor-derived lysate (7.5 × 10^5 cells/ml) for 1 hr, MAPKi for 1 hr then poly I:C/R848 for 24 hr. To investigate the role of DC-derived IL-10 in regulation of IL-12, rhIL-10 was added (0.1–1.0 ng/ml) 4 hr after TLR stimulation (based on published data regarding time of DC secretion of IL-10). Supernatants were harvested and assayed by ELISA for IL-12p70 (BD biosciences), IL-23 (eBioscience), IL-1β, IL-10 (both R&D Abingdon, UK) and IL-6 (Immunotools).

**Western blotting**

MoDC (10^5/well, 12-well plates) and myDC (10^5/well, 96-well plates) were plated in DC medium containing GM-CSF. For experiments directly comparing moDC and myDC, cells were cultured with IL-2 in plates coated with anti-CD3 (1 μg/ml) with 25% DC culture supernatant and anti-CD28 (5 μg/ml). On day 5, cells were harvested and rested for 3 days. Cells were re-stimulated (2 × 10^5/well) with anti-CD3/CD28/IL-2 and Golgi-Plug (BD Pharmingen). After 20 hr, cells were fixed (0.5% formaldehyde), permeabilized (Perm Buffer, Biolegend) and incubated with mouse anti-human Interferon (IFN)γ AF647 (BD Pharmingen), IL-17 FITC (eBioscience) and rat anti-human IL-10 PE (BD Pharmingen). CompBeads (Beckman Coulter High Wycombe, UK) were used for compensation and fluorescence-minus-one (FMO) controls with matched isotypes were used.

**Polarization of naive T cell responses**

DC culture supernatants were generated from 10^5 cells stimulated with poly I:C/R848 ± SB203580. At 12 hr, cells were washed to remove TLR agonists and p38i, and fresh medium added. Supernatants were harvested at 24 hr. Cell-free "mock" supernatants were generated to control for carry-over of TLR agonists/p38i. Naïve T cells (CD4+CD45RA+) were isolated using CD4+ T cell isolation kit II and CD45RA microbeads (Miltenyi) (purity >95%). T cells (2 × 10^7/well) were cultured with IL-2 in plates coated with anti-CD3 (1 μg/ml) with 25% DC culture supernatant and anti-CD28 (5 μg/ml). On day 5, cells were harvested and rested for 3 days. Cells were re-stimulated (2 × 10^5/well) with anti-CD3/CD28/IL-2 and Golgi-Plug (BD Pharmingen). After 20 hr, cells were fixed (0.5% formaldehyde), permeabilized (Perm Buffer, Biolegend) and incubated with mouse anti-human Interferon (IFN)γ AF647 (BD Pharmingen), IL-17 FITC (eBioscience) and rat anti-human IL-10 PE (BD Pharmingen). CompBeads (Beckman Coulter High Wycombe, UK) were used for compensation and fluorescence-minus-one (FMO) controls with matched isotypes were used.

**Whole blood DC enumeration assay and flow cytometry**

300 μl heparinized whole blood was incubated with control or active cocktail of antibodies for 15 min at room temperature. Control cocktail contained mouse anti-human CD19 PE/Cy5 (BD), CD14 PE/Cy5 (Beckman Coulter), IgG1 FITC (Miltenyi) and IgG2a PE (Miltenyi), active cocktail contained CD19 PE/Cy5, CD14 PE/Cy5, CD303 FITC (Miltenyi) and CD1c PE (Miltenyi). 300 μl Cal-Lyse (Invitrogen) was added.
and incubated for 10 min, followed by 3 ml distilled water and incubation for 5 min. Cells were pelleted by centrifugation, resuspended in flow cytometry (FACS) buffer, flowcount fluorospheres (Beckman Coulter) added for absolute enumeration and at least 10^6 events acquired. Comp-beads (BD) were used to set compensation. Optimization and validation of protocol was carried out to ensure reproducibility prior to enumeration of patient DC.

**Statistics**

Cytokine levels are presented as mean ± standard deviation and parametric tests were used where possible with transformations to achieve normality attempted before non-parametric tests used. For analysis of MAPKi on healthy donor cytokine levels, drug-treated cytokine levels are expressed as fold change compared to TLR agonist alone and myDC and moDC compared by one-way ANOVA with Dunnett’s post-test correction. Optimization and validation of protocol was carried out to ensure reproducibility prior to enumeration of patient DC.

**Results**

**Advanced cancer patients have normal numbers of DC**

To determine whether circulating human myDC from cancer patients are a potential therapeutic option for immunotherapy, we established the baseline number and function of DC in patients with fully resected and advanced (Stage 4) cancer. Patient characteristics are shown in Table 1. The staining protocol and analysis strategy were optimized on healthy donors (gating strategy Supporting Information Fig. 1A). Validation experiments and analysis demonstrated reproducible staining and gating (Supporting Information Figs. 1B and 1C). Circulating myDC and plasmacytoid DC numbers (Fig. 1a) in advanced cancer patients (n = 9) were the same as patients with fully resected cancer (n = 8) (p = 0.89 and p = 0.45, respectively) and healthy donors from optimization experiments.

**DC from advanced cancer patients secrete normal levels of cytokines**

Recent work has shown that dual TLR activation of DC is far more effective at inducing cytokine secretion than single
TLR ± IFNγ or cytokine cocktails.\textsuperscript{8,31} Combinations including a TLR7/8 agonist are key to this effect, and therefore poly I:C (TLR3) and R848 (TLR7/8) stimulation was used throughout. There was no significant difference between baseline cytokine production between healthy donors and fully resected or advanced cancer patients for any of the cytokines measured for myDC or moDC (Fig. 1b) except for IL-1β between healthy and resected patients for myDC. However, whilst as a group the cytokine production from Stage 4 patients' myDC was normal (Fig. 1b, top), some patients exhibited markedly reduced cytokine levels, particularly for IL-12.

**Role of MAPK pathways for cytokine production by human DC**

There is a paucity of work concerning intracellular signaling pathways in myDC. Because of the increased clinical use of kinase-inhibitors and emerging immunotherapeutic interest in myDC, we investigated the function of MAPK pathways for cytokine production using healthy donors. In agreement with previous studies,\textsuperscript{11–13} the p38 pathway was crucial for IL-12 production by moDC with secretion substantially suppressed upon p38 inhibition (p38i) [Fig. 2a(i,ii)]. In marked contrast, the p38 pathway in myDC was a potent repressor of IL-12 as a pronounced increase in cytokine secretion was observed following p38i. Despite the common p40 subunit, p38 did not regulate IL-23 in either DC type [Fig. 2a(i,ii)]. IL-6 and IL-1β were similarly not regulated by p38; however, it positively regulated IL-10 production in both moDC and myDC.

In contrast to p38, myDC and moDC responded similarly to inhibition of the MEK-ERK pathway [Fig. 2a(i,ii)] although differences in the magnitude of effect were evident. MEK-ERK had no role in either DC type for IL-12 but was required for IL-1β, IL-23 and IL-10 production. In myDC, the c-Jun N-terminal kinase (JNK) pathway played no role for most cytokines studied. Inhibition with SP600125 suggested that JNK was repressive for IL-23. Conversely, in moDC JNK appeared to play a greater role, as SP600125 suppressed production of IL-12, IL-10 and IL-1β.

An alternate p38i, BIRB0796, was used to confirm that the effects observed were due to differential utilization of p38, and not off-target effects of SB203580. At 0.1 μM, BIRB0796 inhibits p38α and β without known off-target effects\textsuperscript{32} whilst at 1.0 μM it also inhibits p38γ and δ, with some effect on JNK2. In myDC, BIRB0796 (0.1μM) produced a similar increase in IL-12 production to that seen with SB203580 (Fig. 2b). In moDC, BIRB0796 (0.1 μM) halved IL-12 production, with further suppression at 1.0 μM (Fig. 2b). Whilst BIRB0796 did not suppress IL-12 from moDC as much as SB203580, the differential effect on IL-12 production between myDC and moDC was similar.

**Loss of IL-10 is not responsible for myDC IL-12 production following p38i**

IL-10 can inhibit IL-12 production\textsuperscript{33} and we observed that p38-inhibited moDC retained some IL-10 secretion, whilst p38-inhibited myDC did not. We therefore confirmed that loss of IL-10 secretion was not responsible for enhanced IL-12 after p38i in myDC. IL-10 production by DC is first detected 4 hr after TLR stimulation, so IL-10 was added to p38-inhibited, activated myDC at this time point, at concentrations typically secreted in our experiments. Although there was some suppression of IL-12, levels remained substantially higher than TLR-stimulation alone (Fig. 2c) in contrast to the ablation of IL-12 in p38i moDC.
Opposing role of p38 is mediated through MK2

Using a small molecule inhibitor of MK2 we confirmed the role of this molecule in the opposing p38 effect. Blockade of MK2 reduced IL-12 secretion by moDC [Fig. 2d(i)] and increased IL-12 from myDC, whilst IL-10 decreased in both DC types [Fig. 2d(ii)]. Thus, by blocking the p38 pathway at two different levels, we confirmed that it exerts...
opposing roles in myDC and moDC, and established a role for MK2.

**Differential IL-12 gene transcription upon p38 inhibition**

Having established opposing roles for the p38 pathway in moDC and myDC, we determined whether this was transcriptionally regulated. It was previously established that peak transcription of all IL-12 subunits occurs 8–12 hr after TLR stimulation. Furthermore, alterations in IL-12 secretion are typically mediated through changes in peak transcription level rather than transcriptional kinetics, irrespective of TLR agonist. Our previous study established TOP1 as a stable housekeeping gene in moDC and this was confirmed in myDC (Supporting Information Fig. 2). There was minimal expression of p35, p40 and p19 by immature DC (Fig. 2c). As expected, TLR stimulation induced a marked increase in p19, p35 and p40 mRNA in both DC types. Blockade of p38 in moDC decreased p35 mRNA, with minimal change in p40. In complete contrast, blockade of p38 in myDC resulted in a pronounced increase in both p35 and p40 mRNA. The level of p19 mRNA was only moderately increased in both DC types following p38i.

**Differential effect of p38 on Th1-polarization**

The impact of differential p38 usage on Th-responses was determined by priming naive CD4+ T-cells in the presence of cytokine-containing supernatant from p38i myDC or
moDC. Mature myDC and moDC were equally effective at generating Th1 responses (Fig. 3). In keeping with the loss of IL-12, inhibition of p38 in moDC reduced Th1 responses to baseline levels. In contrast, p38i myDC effectively generated Th1 responses. The effect on Th-17 polarization was more subtle and there was no effect on Treg polarization (IL-10). Importantly, cell-free “mock supernatants,” used to control for carry-over of TLR agonists and MAPK inhibitors, showed no difference to αCD3/αCD28/IL-2 alone (Supporting Information Fig. 3).

P38 activates Rsk via MK2 in human DC
Having established that the differential effect of p38 signaling was mediated via MK2, we searched for candidate mechanisms. In murine DC, Watts and coworkers described a unique mechanism of Rsk phosphorylation by p38-MK2, where blockade of both p38 and ERK was required to fully prevent Rsk activation upon TLR stimulation [Fig. 4a(i)],36 in contrast to all other cell types where Rsk is activated exclusively through MEK-ERK [Fig. 4a(ii)]. This is important as GSK3β, a downstream target of Rsk, is involved in IL-10 and IL-12 regulation [Fig. 4a(iii)].37 To date this p38-MK2-Rsk link has not been

![Diagram](image-url)
demonstrated in human DC and we hypothesized that its absence in human moDC could account for our findings.

In order to study signaling downstream of p38 we first established the time-course of MK2 activation. Immature myDC and moDC did not express phospho-MK2 [Fig. 4b(iii)], however MK2 phosphorylation was induced within 15 min of poly LC/R848 treatment. In moDC, phospho-MK2 levels plateaued after 15 min, and returned to near baseline by 1 hr. In myDC, MK2 phosphorylation peaked at 30 min before decreasing. Although the absolute level of MK2 activation per cell was greater in moDC than myDC [Fig. 4b(i)], when corrected for cell size using β-actin [Fig. 4b(ii)], myDC appeared to have more prominent MK2 activation than moDC.

We confirmed that the inhibitors were blocking downstream p38 signaling by measuring MK2 phosphorylation in moDC (Fig. 4c). Treatment with SB203580 or BIRB0796 1.0 μM prevented TLR-induced MK2 phosphorylation, whereas 0.1 μM BIRB0796 did not fully inhibit MK2 activation. As expected, MEKi did not affect phospho-MK2 levels (Fig. 4c) or p38 activation (Fig. 4d) but ablated ERK phosphorylation (Fig. 4d).

ERK sequentially phosphorylates Rsk at multiple residues before downstream signaling occurs, whilst p38 leads directly to phosphorylation of the S380 residue in DC, bypassing earlier steps [Fig. 4a(iv)]. RskS380 phosphorylation is the penultimate step before downstream signaling occurs and is the point at which p38 and ERK activation of Rsk converge in murine DC. Poly LC/R848 induced phosphorylation of ERK, p38 and Rsk at all residues studied (Fig. 4d). Inhibition of p38 increased ERK and Rsk phosphorylation at all residues (presumably due to loss of negative feedback). Rsk phosphorylation at T359/S363 and T373 was prevented by U0126, in keeping with the sequence of phosphorylation events. Residual phosphorylation of RskS380 remained following U0126 treatment, and this was reproducibly (but subtly) further reduced by BIRB0796 (Fig. 4d).

In human myDC, we found that TLR-dependent phosphorylation of MK2 and RskS380 was similar to moDC (Fig. 4e). BIRB0796 prevented MK2 phosphorylation but increased phospho-RskS380. The residual level of phospho-RskS380 after MEKi was small, and whilst it reduced further with simultaneous p38i, this effect was subtle. Importantly, there was no difference in the pattern of RskS380 phosphorylation between moDC and myDC. Nevertheless, we demonstrated for the first time that the p38-MK2-Rsk signaling link exists in human DC, though p38 appeared to play a much lesser role in Rsk activation than in murine DC.

P38 inhibition permits normal IL-12 secretion in myDC from advanced cancer patients

Having established a differential role for the p38 pathway in healthy donor DC IL-12 production, we explored whether this still applied in advanced cancer patients. We found that p38i (SB203580) was still able to enhance IL-12 and suppress IL-10 in advanced cancer patients (Fig. 5a, p = 0.0015 for IL-12, p = 0.0025 for IL-10) without affecting other cytokines (not shown). Importantly, in those patients with undetectable baseline secretion, p38i increased IL-12 production to at least normal baseline levels.

Melanoma lysate suppresses IL-12 in myDC; restoration by p38i

Previously, we showed that exposure of moDC to melanoma TDL impaired IL-12 and Th-1 responses. Since TDL is used for antigen loading in DC vaccination protocols, we established whether cancer patient myDC were similarly susceptible. In all cancer patient myDC treated with melanoma TDL, suppression of IL-12 was seen (Fig. 5b). Levels of other cytokines were less affected, though there was some suppression of IL-23, IL-1β and IL-6. Treatment with p38i (SB203580) prior to TDL pulsing restored the ability of myDC to secrete IL-12 in 6/8 cancer patients and still suppressed IL-10 in all donors (Fig. 5c). Thus, enhancement of IL-12 production in myDC due to p38 inhibition is potent enough to overcome the severely suppressive effects of TDL treatment, at the same time as continuing to suppress IL-10 secretion.

Discussion

We demonstrate that cancer patients have sufficient numbers of myDC to be a viable immunotherapy option. Several studies have enumerated circulating DC with mixed findings, some showing depressed number in advanced cancer and others not, leaving this question unresolved. It has previously been difficult to accurately and directly quantify circulating DC but the identification of specific markers and development of reagents allowing direct enumeration make accurate quantification possible. In this study with a limited number of patients, there were sufficient myDC to harvest for cellular therapy, with no difference between resected and Stage 4 groups.

Cytokine secretion was also normal in the majority of patients. To our knowledge, there has been no previous study of the cytokine profile of purified cancer patient myDC, eliminating potential modifying effects of other cell types as would be the case with un-purified cells. We describe for the first time that the p38-MK2 pathway negatively regulates IL-12 in human myDC. This contrasts with the established positive role for p38 in moDC for IL-12. Our findings have implications for the utilization of myDC in cancer immunotherapy and for use of p38i in cancer and autoimmunity. We demonstrated that enhancement of IL-12 after p38i occurs in myDC from advanced cancer patients, including in those with severely impaired cytokine production. This negative role for p38 in myDC was surprising, given its conventionally accepted role in inflammation and the fact that moDC rely on p38 for IL-12 and consequent Th1 polarization. More recently, however, it has been shown that p38 signaling can lead to anti-inflammatory responses and that the requirement for p38 during induction of inflammation is tissue- and stimulus-specific. We obtained similar results with two
selective p38 inhibitors, SB203580 and BIRB0796, and an MK2 inhibitor further confirmed the p38-dependence of this observation.

The differential involvement of the link allowing p38 to activate Rsk (mediated through MK2) could have accounted for the opposing roles of p38 in myDC and moDC. However, the pattern of Rsk phosphorylation with p38i, MEKi or dual blockade was similar in both DC types, discounting this as the mechanism. It would appear that the p38-Rsk signaling link is less important in human DC than murine DC, as only a small amount of Rsk activity remained when MEK-ERK was blocked and further reduction with both inhibitors was small. MK2 has multiple downstream ligands, including HSP27, LSP1, CREB, ATF1, SRF, tyrosine hydrolase and TTP and is involved in a variety of cellular processes. Other than the p38-MK2-Rsk-GSK3β candidate mechanism eliminated in this study, a review of the literature does not reveal any alternate mechanisms to explore. Further work to establish the down-stream targets of MK2 responsible for the opposing effects on IL-12 production between myDC and moDC will require detailed analysis of transcription factor binding to the differentially affected IL12A gene.

Whilst the decrease in IL-12 from moDC after p38i suppressed Th1 polarization, the increase in IL-12 in myDC did not further induce Th1 responses in healthy donors. It could be that levels of IL-12 were already optimal, or IL-10 may play a role. IL-10 is secreted earlier than IL-12, and the experimental procedure requires removal of TLR agonists/drugs to prevent their direct impact on T-cells. As the time-frame for washing cells overlapped with secretion of IL-10 any beneficial effect of suppressing IL-10 may not be evident in the T-cell stimulations. In patients with severely impaired IL-12 production, p38i restored secretion to normal and it is possible that p38i could recover deficient Th1 polarization in these patients. Due to restrictions on venipuncture (hence leucocytes) in our advanced cancer patients, it was not possible to undertake Th1 polarization studies. However, this will form an important part of our pre-clinical study and the activation of T-cell responses by DC:T-cell co-cultures will be determined.

Treatment of cancer patient myDC with TDL suppressed IL-12. Firstly, this showed that the Stage 4 patients in this study were not “resistant” to the suppressive effects of tumor.

Figure 5. Effect of melanoma lysate with or without p38 inhibitor on cytokine production by myDC from cancer patients. (a) MyDC (n = 7) from advanced cancer patients were treated in triplicate with p38 inhibitor SB203580 prior to poly I:C/R848. At 24 hr cytokine secretion was analyzed by ELISA. Shown is mean secretion of IL-12p70 and IL-10 for each patient plotted separately with poly I:C/R848 alone and with pre-treatment with MAPK inhibitor. (b) MyDC from fully resected (open circles, n = 7) and Stage 4 (filled circles, n = 8) cancer patients were treated for 1 hr with MM418 TDL before stimulation for 24 hr with poly I:C/R848. Cytokine secretion as a percentage remaining compared to stimulation without pre-treatment with TDL was calculated for each donor. (c) MyDC (individual symbols for each patient, n = 8) from advanced and fully resected cancer patients were treated as in (b) but with 1 hr pre-treatment with p38 inhibitor SB203580 prior to TDL treatment and TLR stimulation. Cytokine production (IL-12p70 and IL-10) for each condition for each donor is plotted. p < 0.05 (*) and p < 0.005 (**).
but rather that their cells had not been significantly impaired in vivo since their baseline cytokine secretion was normal. Secondly, it confirmed our previous observations regarding the detrimental effect of freeze-thaw TDL as an antigen source. TDL is attractive since it provides multiple antigens and is not restricted to specific HLA types. Recent work has focused on generating more immunogenic lysates using heat-shock or radiation prior to lysis or the conjugation of virus-like particles to lysate before DC loading, but our study confirmed that conventional freeze-thaw TDL is suppressive and thus should be treated with caution as an anti-gen source.

Our study has important implications for the efficacy of p38i currently being tested in autoimmune/inflammatory conditions. If p38i in vivo mirrors the observed ex vivo effects then systemic administration of p38i may increase IL-12 production, contrary to the intended anti-inflammatory effect. That MK2 blockade produced a similar cytokine profile in myDC as p38i raises the possibility of targeting MK2 to support Th1 responses. Clinical use of p38i has been hampered by side effects of liver toxicity and rashes, which may be due to off-target effects on other pathways, or to blockade of all downstream functions of p38. In order to alter myDC IL-12 production and hence enhance Th1 polarization it may be sufficient to block only MK2, avoiding effects on other facets of p38 signaling. Further work is required to explore in more detail the effects of MK2i on myDC. In cancer, p38i are being tested for their direct anti-tumor effect and our observations raise the possibility of combining systemic p38i with targeted immunotherapeutic approaches.

Using whole peripheral blood as a source may not yield adequate cell numbers as 500 ml would typically yield 1.5 x 10⁶ myDC. It has been shown that CD1c⁺ myDC can be isolated in a GMP-approved manner for clinical use in sufficient numbers from a leucopheresis procedure, with a mean of 13.8 x 10⁶ PBMC and 39.5 x 10⁶ CD1c⁺ DC obtained with mean 86% purity. The number of myDC which could be administered per vaccination may be lower than in moDC clinical trials (which typically administer 5 x 10⁶ to 5 x 10⁷ moDC per vaccination); however if the pre-clinical data on myDC regarding increased ability to migrate and enhanced T-cell stimulatory capacity is confirmed, the net “immune potency” per vaccination may be substantially improved despite smaller cell numbers. We are therefore embarking on a pre-clinical feasibility study to establish the necessary systems for isolation of sufficient myDC from cancer patients, with the aim of initiating a phase I study of adoptively transferred myDC treated with p38i.

In cancer patients, circulating myDC are present in sufficient numbers to allow their use as a therapeutic product. As a group their cytokine secretion after TLR stimulation is normal and even in individuals with impaired cytokine production, p38i restores IL-12 to normal levels. Further development of p38-inhibited circulating myDC as a therapeutic strategy for cancer is warranted.

Acknowledgements
The authors would like to thank Dr Stephen Keyse, Dr Rosanna Zaru and Professor Colin Watts (University of Dundee) for advice regarding p38 and Rsk signaling in dendritic cells. Authors are also grateful to Dr Karen Robinson and Professor Peter Shaw for critical reading of our manuscript.

Author Contributions

References